Mani Foroohar
Stock Analyst at Leerink Partners
(3.25)
# 1,077
Out of 5,044 analysts
171
Total ratings
52.13%
Success rate
1.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Maintains: Outperform | $9 → $20 | $10.08 | +98.41% | 6 | Oct 7, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Market Perform | $9 → $7 | $3.97 | +76.32% | 13 | Oct 3, 2025 | |
| MRNA Moderna | Maintains: Underperform | $18 → $15 | $25.35 | -40.83% | 18 | Aug 22, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Market Perform | $45 → $10 | $24.22 | -58.71% | 2 | Jul 21, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $5.91 | +1.52% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $11.97 | +125.56% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $30.96 | +132.56% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $3.91 | +334.78% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $70.51 | -30.51% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $64.50 | -28.68% | 15 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $22 | $7.59 | +189.86% | 6 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $53 → $62 | $73.57 | -15.73% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $16.17 | -19.60% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $21.77 | +33.21% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.37 | -25.51% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $13.16 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $7.81 | +296.93% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.56 | +348.72% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $39.55 | +1.14% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $13.96 | +501.72% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $3.17 | +120.82% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $26.43 | +191.34% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $475.91 | -69.95% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.28 | +13.64% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $64.17 | +18.44% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.47 | +1,276.52% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $4.26 | +369.48% | 6 | Jul 23, 2021 |
Lexeo Therapeutics
Oct 7, 2025
Maintains: Outperform
Price Target: $9 → $20
Current: $10.08
Upside: +98.41%
Rocket Pharmaceuticals
Oct 3, 2025
Maintains: Market Perform
Price Target: $9 → $7
Current: $3.97
Upside: +76.32%
Moderna
Aug 22, 2025
Maintains: Underperform
Price Target: $18 → $15
Current: $25.35
Upside: -40.83%
Sarepta Therapeutics
Jul 21, 2025
Downgrades: Market Perform
Price Target: $45 → $10
Current: $24.22
Upside: -58.71%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $5.91
Upside: +1.52%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $11.97
Upside: +125.56%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $30.96
Upside: +132.56%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $3.91
Upside: +334.78%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $70.51
Upside: -30.51%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $64.50
Upside: -28.68%
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $7.59
Upside: +189.86%
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $73.57
Upside: -15.73%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $16.17
Upside: -19.60%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $21.77
Upside: +33.21%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.37
Upside: -25.51%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $13.16
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $7.81
Upside: +296.93%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $1.56
Upside: +348.72%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $39.55
Upside: +1.14%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $13.96
Upside: +501.72%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $3.17
Upside: +120.82%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $26.43
Upside: +191.34%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $475.91
Upside: -69.95%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.28
Upside: +13.64%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $64.17
Upside: +18.44%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.47
Upside: +1,276.52%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $4.26
Upside: +369.48%